Stockscreener 앱 받기
16.61
2.52%
-0.43
시간 외 거래:
16.61
전일 마감가:
$17.04
열려 있는:
$17.16
하루 거래량:
209.65K
Relative Volume:
0.31
시가총액:
$506.04M
수익:
-
순이익/손실:
$-168.05M
주가수익비율:
-3.2378
EPS:
-5.13
순현금흐름:
$-146.15M
1주 성능:
-3.65%
1개월 성능:
-12.02%
6개월 성능:
+21.15%
1년 성능:
+62.84%
1일 변동 폭
$16.55
$17.17
1주일 범위
$16.31
$17.90
52주 변동 폭
$9.12
$22.55
Keros Therapeutics Inc Stock (KROS) Company Profile
명칭
Keros Therapeutics Inc
전화
617-314-6297
주소
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
Compare KROS vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KROS
Keros Therapeutics Inc
|
16.61 | 519.14M | 0 | -168.05M | -146.15M | -5.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-20 | 개시 | Wells Fargo | Overweight |
| 2025-06-10 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2025-01-21 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2025-01-17 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2024-12-16 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-12-16 | 재확인 | Oppenheimer | Outperform |
| 2024-12-13 | 재확인 | H.C. Wainwright | Buy |
| 2024-12-12 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2024-12-12 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2024-12-12 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2024-11-05 | 개시 | Jefferies | Buy |
| 2024-10-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-09-23 | 개시 | Guggenheim | Buy |
| 2024-06-25 | 개시 | Oppenheimer | Outperform |
| 2024-02-21 | 개시 | William Blair | Outperform |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2023-07-31 | 개시 | Wedbush | Outperform |
| 2023-07-26 | 개시 | BofA Securities | Buy |
| 2023-02-14 | 개시 | Cowen | Outperform |
| 2022-10-18 | 개시 | Truist | Buy |
| 2022-07-26 | 개시 | BTIG Research | Buy |
| 2020-12-08 | 재확인 | H.C. Wainwright | Buy |
| 2020-05-04 | 개시 | H.C. Wainwright | Buy |
| 2020-05-04 | 개시 | Jefferies | Buy |
| 2020-05-04 | 개시 | Piper Sandler | Overweight |
| 2020-05-04 | 개시 | SVB Leerink | Outperform |
모두보기
Keros Therapeutics Inc 주식(KROS)의 최신 뉴스
Why Keros Therapeutics Inc. stock could see breakout soonEarnings Risk Summary & Fast Moving Stock Trade Plans - mfd.ru
Keros Therapeutics: Key Catalysts and Financial Runway in Focus - AD HOC NEWS
Price-Driven Insight from (KROS) for Rule-Based Strategy - Stock Traders Daily
Y Intercept Hong Kong Ltd Lowers Holdings in Keros Therapeutics, Inc. $KROS - MarketBeat
Keros Therapeutics, Inc. $KROS Shares Sold by Federated Hermes Inc. - MarketBeat
Big Picture: What is SIDUs revenue forecastGap Up & Weekly Breakout Opportunity Watchlist - baoquankhu1.vn
Risk Report: What is the next catalyst for Keros Therapeutics IncDividend Hike & High Accuracy Trade Alerts - baoquankhu1.vn
Tech Rally: Is CleanCore Solutions Incs ROE strong enough2025 Stock Rankings & Risk Managed Trade Strategies - baoquankhu1.vn
Aug Opening: Will HUB Cyber Security Ltd. Equity Warrant outperform during market ralliesJuly 2025 WrapUp & Target Return Focused Stock Picks - baoquankhu1.vn
Keros Therapeutics vs. Dyne: Which DMD Biotech Has More Upside? - Nasdaq
Portfolio Shifts: Can NECB benefit from deglobalizationJuly 2025 Reactions & Community Driven Trade Alerts - baoquankhu1.vn
Market Wrap: What is the next catalyst for Keros Therapeutics IncAnalyst Downgrade & Capital Efficiency Focused Ideas - baoquankhu1.vn
Is KROS' KER-065 the Next Breakthrough in DMD Space? - The Globe and Mail
(KROS) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
MRKR stock up nearly 114% in 3 months: Here's what you need to know - MSN
Wall Street Analysts See a 42.78% Upside in Keros Therapeutics (KROS): Can the Stock Really Move This High? - MSN
Fund Flows: Does Keros Therapeutics Inc stock reflect fundamentalsWeekly Profit Report & Smart Investment Allocation Tips - baoquankhu1.vn
Is Keros Therapeutics Inc. backed by strong institutional buyingQuarterly Trade Summary & AI Driven Price Predictions - mfd.ru
JANX Enters Global Oncology Collaboration With BMY, Stock Rises - Nasdaq
Keros Therapeutics, Inc. (KROS) Investor Outlook: Exploring a Promising 20.76% Potential Upside - DirectorsTalk Interviews
Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
MRKR Stock Up Nearly 114% in 3 Months: Here's What You Need to Know - Finviz
Will KROS Stock's Restructuring Efforts Reap Rewards for Investors? - sharewise.com
Axsome Therapeutics Begins Phase III Study on AXS-14 for Fibromyalgia - Finviz
KROS Stock Surges 85.6% in a Year: More Upside Potential in 2026? - sharewise.com
CG Oncology Stock Rallies Nearly 32% in a Week: Here is Why - Finviz
(KROS) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
TVTX Stock Falls as FDA Extends Review Timeline for Filspari sNDA - Finviz
Downgrade Watch: What’s the RSI of Keros Therapeutics Inc. stock2025 Performance Recap & Long-Term Safe Investment Plans - baoquankhu1.vn
TG Therapeutics Stock Rises 7% on Strong Q4 & 2025 Preliminary Results - Finviz
Aug Technicals: Is Keros Therapeutics Inc likely to announce a buybackJuly 2025 Reactions & Entry Point Confirmation Signals - baoquankhu1.vn
History Review: What are Keros Therapeutics Incs technical support levelsJuly 2025 Analyst Calls & Community Consensus Trade Alerts - baoquankhu1.vn
BEAM Outlines Key Strategic & Pipeline Goals for 2026, Stock Rises - Zacks Investment Research
MACD Signal: Whats the fair value of Keros Therapeutics Inc stock2025 Key Highlights & Free Daily Entry Point Trade Alerts - baoquankhu1.vn
INSM Stock Jumps on 2025 Preliminary Sales, 2026 Goals Announced - Finviz
Keros Therapeutics, Inc. (KROS) Stock Analysis: Strong Revenue Growth and a 26% Potential Upside - DirectorsTalk Interviews
Will Keros Therapeutics Inc. stock outperform value stocks2025 Macro Impact & Weekly Breakout Opportunity Watchlist - Улправда
How rising interest rates impact Keros Therapeutics Inc. stockJuly 2025 Chart Watch & Verified Stock Trade Ideas - Улправда
What analysts say about Keros Therapeutics Inc stockSector Rotation Strategies & Real-Life Case Studies You Can Follow - earlytimes.in
Bank of America Securities Keeps Their Hold Rating on Keros Therapeutics (KROS) - The Globe and Mail
Keros Therapeutics (NASDAQ:KROS) Trading Down 3.3% on Analyst Downgrade - Defense World
Keros Therapeutics (NASDAQ:KROS) Cut to “Hold” at Zacks Research - Defense World
(KROS) Risk Channels and Responsive Allocation - Stock Traders Daily
Keros Therapeutics (NASDAQ:KROS) Downgraded to Hold Rating by Zacks Research - MarketBeat
Keros Therapeutics (NASDAQ:KROS) Stock Price Down 3.3%Time to Sell? - MarketBeat
Zacks.com featured highlights include AES, BorgWarner, Enersys, PG&E and Keros Therapeutics - Yahoo Finance
Short Interest in Keros Therapeutics, Inc. (NASDAQ:KROS) Drops By 16.6% - MarketBeat
5 Low Price-to-Book Stocks to Buy as 2025 Comes to a Close - Yahoo Finance
KROS or ARGX: Which Is the Better Value Stock Right Now? - sharewise.com
Keros Therapeutics Inc (KROS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.24%
0.19%
자본화:
|
볼륨(24시간):